"Dipeptidyl Peptidase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine protease that catalyses the release of an N-terminal dipeptide. Several biologically-active peptides have been identified as dipeptidyl peptidase 4 substrates including INCRETINS; NEUROPEPTIDES; and CHEMOKINES. The protein is also found bound to ADENOSINE DEAMINASE on the T-CELL surface and is believed to play a role in T-cell activation.
| Descriptor ID |
D018819
|
| MeSH Number(s) |
D08.811.277.656.350.350.126 D08.811.277.656.959.250 D23.050.301.264.894.160 D23.101.100.894.160
|
| Concept/Terms |
Dipeptidyl Peptidase 4- Dipeptidyl Peptidase 4
- CD26 Antigen
- Antigen, CD26
- Antigens, CD26
- Adenosine Deaminase Complexing Protein 2
- Dipeptidyl-Peptidase IV
- Dipeptidyl Peptidase IV
- CD26 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl Peptidase 4".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl Peptidase 4".
This graph shows the total number of publications written about "Dipeptidyl Peptidase 4" by people in this website by year, and whether "Dipeptidyl Peptidase 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dipeptidyl Peptidase 4" by people in Profiles.
-
Selective refueling of CAR T?cells using ADA1 and CD26 boosts antitumor immunity. Cell Rep Med. 2024 May 21; 5(5):101530.
-
Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins. J Biomol Struct Dyn. 2024 May; 42(8):4029-4047.
-
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. Hypertension. 2022 04; 79(4):827-835.
-
Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4. J Invest Dermatol. 2022 06; 142(6):1597-1606.e9.
-
Angiotensin-converting Enzyme 2-containing Small Extracellular Vesicles and Exomeres Bind the Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. Gastroenterology. 2021 02; 160(3):958-961.e3.
-
Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat Commun. 2020 01 07; 11(1):87.
-
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res Cardiol. 2019 08 06; 114(5):35.
-
Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model. Int J Mol Sci. 2018 Oct 18; 19(10).
-
Hippo Signaling Plays an Essential Role in Cell State Transitions during Cardiac Fibroblast Development. Dev Cell. 2018 04 23; 45(2):153-169.e6.
-
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.